Business · 1 sources covering this

HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·1h ago
HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead
The bank's analysts wrote in a note on Monday that they have downgraded the stock to 'hold', as the team "no longer finds the risk-reward balance attractive."
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/6a04f478c344cd6b9337f17d0144dc79228a04ec"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead"></iframe>

HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

How 1 sources are covering this

HSBC loses conviction in leading drugmaker, forecasts 'tough path' ahead

More from Business

US inflation rate eases to 3.5% as gasoline prices fall

Bank earnings live updates: JPMorgan and Bank of America calls are underway

Oil Rises Above $85 a Barrel as Gulf Clash Escalates

Warsh to Reiterate Fed’s Pledge to Get Inflation Down

Reader

Trust & legal

Across the network